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Brief Communication
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Metronomic chemotherapy (MCT) is a novel therapeutic strategy for cancer treatment endowed with an
antiangiogenic effect. It refers to regular administration of low doses of cytotoxic drugs, with minimal or
no drug-free breaks. Previously, we demonstrated the immunomodulating activity of a single low-dose of
cyclophosphamide (Cy) and the antitumor effect of MCT with Cy on established rat lymphomas and sarco-
mas. Here, we examined whether the immune response is responsible for the antitumor effect of MCT with
Cy on L-TACB lymphoma. Inbred e rats and nude mice were subcutaneously challenged with L-TACB.
After 7 days, they were distributed into two experimental groups: 1) treated animals, which were injected
IP with Cy (10 mg/kg body weight) three times per week, and 2) control animals, which received IP saline
injections. Exponential growth and decay and tumor doubling time were calculated. Also, serum IL-10 levels
were measured. One hundred percent of treated rats showed tumor regression versus 0% of control rats. The
increase of tumor-induced IL-10 levels was reverted by the treatment with Cy. On the other hand, there
were no tumor regressions, in treated or control nude mice. However, the tumor doubling times of treated
nude mice were significantly higher than those of control mice, implying that other antitumor mechanism(s),
independent of the adaptive immune response, might be taking place. Our present results indicate that modu-
lation of the immune response would be involved in the antitumor effect of MCT with Cy, because the
absence of the specific immune response impairs, at least in part, its therapeutic effect in a lymphoma tumor
model.
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INTRODUCTION apy (100% and 83% complete tumor regression, respec-
tively), that does not cause loss of weight and is devoid
of hematological, cardiac, hepatic, and renal toxicity (7).Metronomic chemotherapy (MCT) is a novel thera-
peutic strategy for cancer treatment. It refers to regular Preclinical and clinical experiments have shown that the
therapeutic effect of MCT is achieved through inhibitionadministration of comparatively low doses of cytotoxic
drugs, with minimal or no drug-free breaks, over pro- of angiogenesis (1,8,9). Our objective here was to inves-
tigate whether the immune response is also responsiblelonged periods of time (1). We have previously demon-
strated that a single low dose of cyclophosphamide (Cy), for the antitumor effect obtained with metronomic ad-
ministration of Cy in a rat lymphoma model.a treatment completely devoid of toxicity, inhibits the
growth of spontaneous and experimental metastasis of a
rat lymphoma, while it does not affect primary tumor MATERIALS AND METHODS
growth (2). Such an effect would be mainly due to mod- Animals
ulation of the immune response (3–6). We also demon-
strated that administration of Cy at low doses on a thrice Inbred adult female IIM e/Fm rats (10) from the Fa-
cultad de Ciencias Me´dicas, Universidad Nacional deweekly schedule, with no rest periods, to established rat
lymphomas and sarcomas is a successful antitumor ther- Rosario breeding facilities and N:NIH (S)-nu nude mice
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from Universidad Nacional de La Plata breeding facili- (days), and 0.69/k = doubling time. Goodness of fit was
quantified by the coefficient of determination (R2), andties were used for these study. The animals were fed
with commercial chow and water ad libitum, and were also judged by the convergent on a solution and the sig-
nificance of a runs test performed to verify the randommaintained in a 12-h light/dark cycle. All the experi-
ments were done during the first half of the light cycle distribution of the residuals. For statistical analysis, dou-
bling time was treated as a new random variable andand in accordance with animal care standards of the in-
stitution, which complies with the guidelines issued by differences between groups were analyzed with the non-
parametric Mann-Whitney U-test.the Canadian Council on Animal Care.
All the statistical tests were done with the GraphPad
Prism version 3.0 (GraphPad Software, San Diego,Cyclophosphamide
CA, USA). Differences were considered to be statisti-Cyclophosphamide (Cy) was obtained from Labora-
cally significant at p < 0.05.
torio Filaxis, SA, Argentina. It was dissolved in sterile
distilled water to a concentration of 20 mg/ml.
RESULTS AND DISCUSSION
Tumor The antiangiogenic mechanism of action of MCT, be
it normalization of tumor vasculature, inhibition of re-Lymphoma L-TACB is a poorly differentiated B-cell
lymphoma, which arose spontaneously in an inbred e rat population of tumor cells, or amplification of the anti-
vascular effects of chemotherapy (12), is nowadays(11) and it is maintained by in vivo periodic challenge
in syngeneic rats. widely accepted. Nevertheless, other mechanisms may
well contribute to the therapeutic effect of MCT, mainly
depending on the chemotherapeutic agent administered.Experimental Model
Cyclophosphamide is the alkylating agent most com-Adult e rats and nude mice were subcutaneously chal-
monly used in cancer chemotherapy and one of the firstlenged with L-TACB by trocar (day 0). When tumors
cytotoxic drugs employed in metronomic chemotherapy
were detectable (day 7), animals were distributed as fol- (13). While high doses of Cy [i.e. maximum toleratedlows: treated rats—e rats (n = 6) were injected IP with dose (MTD)] cause immunosuppression, a single lowCy (10 mg/kg body weight) three times per week, from dose has an immunomodulatory effect (4,5,14,15). Thus,day 7; control rats—e rats (n = 6) were injected IP with
our question was if the regular administration of low
saline three times per week, from day 7; treated mice— doses of Cy would cause stimulation of the antitumor
nude mice (n = 7) treated the same as treated rats; con- immune response like a single low dose does, or would
trol mice—nude mice (n = 7) treated the same as control induce its suppression, like Cy when it is administered
rats. Tumors were measured twice weekly and tumor in the MTD. Hence, we examined whether the therapeu-
volumes were calculated as follows: V = 0.4 (ab2),
tic effect obtained when low doses of Cy are adminis-
where V = volume (mm3), a = largest diameter (mm),
tered with no significant breaks in tumor-bearing ani-
and b = smallest diameter (mm). The experiments ended
mals involves the adaptive immune response.
on day 19 (rats) or day 17 (nude mice), or when animals Cross-species comparisons have been consistently
reached the maximum permitted tumor volume. Blood
used to evaluate the efficacy of different antitumor treat-
samples, taken from the tail vein of e rats, were col-
ments in an environment devoid of specific immune re-lected on day 0 (basal level, before tumor inoculation)
sponse. Therefore, we developed syngeneic and xenoge-
and at the end of the experiments, and were stored at
neic models in which euthymic rats and athymic nude
−20°C until used. IL-10 serum levels were measured by
mice were challenged with L-TACB. The treated groups
a sandwich ELISA assay (OptEIATM, BD Biosciences
received low dose Cy in a metronomic schedule, begin-Pharmingen, San Diego, CA, USA), in duplicate.
ning the treatment on day 7, when tumors reached a
mean volume of 520 and 460 mm3 in rats and nudeStatistics
mice, respectively. After a short period of tumor growth
that lasted until day 12, 100% of treated rats showedExponential growth and decay were calculated apply-
ing an exponential regression curve and one-phase expo- sustained tumor regression (Fig. 1A, inset) versus 0% of
control rats (Fig. 1B). We analyzed the exponentialnential decay curve, respectively. For tumor volume
doubling time (TvDT), a nonlinear estimation procedure growth and decay of the treated (Fig. 1A, left and right,
respectively) and control rat tumors (Fig. 1B). We foundwas used to fit the experimental individual tumor vol-
ume–time data, set with an exponential model: V(t) = that during the growing phase, TvDT (tumor volume
doubling time) was higher (slower growth rate) inStart.exp (k.t), where V(t) = tumor volume at time t,
Start = tumor volume at time 0, k = constant, t = time treated rats than in control rats and the difference was
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Figure 1. Effect of MCT with Cy in euthymic rats challenged with L-TACB lymphoma. (A, left panel) Exponential growth
curves of individual treated rats; (A, right panel) exponential decay curves of individual treated rats. Inset: Individual tumor
growth curves of treated rats. (B) Exponential growth curves of individual control rats. (C) Median tumor volume doubling times
(TvDT) of control and treated rats. Control versus treated rats: p = 0.057, Mann-Whitney’s U-test.
marginally significant (p = 0.057) (Fig. 1C). This out- immunopotentiation induced by treatment of tumor-
bearing rats with a single low-dose Cy is mainly medi-come emphasized the early tumor response to metro-
nomic chemotherapy. ated by a reduction in T-cell-derived IL-10 production
(5). Accordingly, we measured IL-10 serum levels in L-Interestingly, neither treated (Fig. 2A) nor control
nude mice (Fig. 2B) showed signs of tumor regression. TACB-bearing rats treated with Cy in an MCT schedule.
As shown in Figure 3, IL-10 levels in control rats in-The contrasting response in treated rats and mice sug-
gests the involvement of the adaptive immune response creased significantly with tumor progression (ANOVA,
p = 0.0124; basal versus control: Tukey-Kramer, p <in the antitumor effect of MCT with Cy in the L-TACB
tumor model. We have previously demonstrated in the 0.01). However, the levels of IL-10 in MTC-treated tu-
mor-bearing rats did not differ from basal levels.same model that the shift from immunosuppression to
Figure 2. Effect of MCT with Cy in nude mice challenged with L-TACB lymphoma. (A) Exponential growth curves of individual
treated mice. (B) Exponential growth curves of individual control mice. (C) Median tumor volume doubling times (TvDT) of
control and treated mice. Control versus treated mice: p = 0.002, Mann-Whitney test.
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sponse when administered in a metronomic fashion.
This mechanism could be exploited therapeutically in
order to increase the efficacy of the treatment. The clini-
cal efficacy obtained with metronomic low-dose cyclo-
phosphamide therapy in a patient with an advanced
mucosa-associated lymphoid tissue lymphoma (19)
underlines the importance of improving this therapeutic
modality. Also it suggests the necessity of studying the
relationship between other drugs usually employed in
metronomic schedules and the immune system.
In summary, MCT with cyclophosphamide, a thera-
peutic modality that was initially thought as mainly anti-Figure 3. Measurement of serum IL-10 concentration in e rats
angiogenic exerts, in addition, an immune system-medi-before L-TACB inoculation (basal), and in L-TACB-bearing
rats treated with saline (control) or MCT with Cy (treated), at ated effect in a B-cell lymphoma tumor model. This
the end of the experiment (day 19 or when animals reached knowledge will possibly lead to the proposal of novel
the maximum permitted tumor volume). Data are expressed as
combinations of antiangiogenic protocols and immuno-
mean (bars, SEM) serum concentration. ANOVA, p = 0.0124;
therapy that may collaborate in the fight against lym-*basal versus control: p < 0.01, Tukey-Kramer multiple com-
phoma.parison test.
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